Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.94 Billion KRW | -119.27% |
| 2022 | 108.66 Billion KRW | 8046.51% |
| 2021 | -1.36 Billion KRW | -142.47% |
| 2020 | 3.22 Billion KRW | -52.07% |
| 2019 | 6.71 Billion KRW | 128.09% |
| 2018 | 2.94 Billion KRW | 12.05% |
| 2017 | 2.62 Billion KRW | -12.88% |
| 2016 | 3.01 Billion KRW | -96.95% |
| 2015 | 98.85 Billion KRW | 2350.18% |
| 2014 | 4.03 Billion KRW | -49.28% |
| 2013 | 7.95 Billion KRW | -78.18% |
| 2012 | 36.45 Billion KRW | 3.9% |
| 2011 | 35.08 Billion KRW | 457.1% |
| 2010 | 6.29 Billion KRW | -21.77% |
| 2009 | 8.04 Billion KRW | -76.44% |
| 2008 | 34.16 Billion KRW | 93.01% |
| 2007 | 17.69 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -666.64 Million KRW | 98.32% |
| 2024 Q2 | -421.8 Million KRW | 36.73% |
| 2023 FY | -20.94 Billion KRW | -119.27% |
| 2023 Q1 | 15.49 Billion KRW | 918.02% |
| 2023 Q4 | -39.7 Billion KRW | -985.95% |
| 2023 Q3 | 4.48 Billion KRW | 468.96% |
| 2023 Q2 | -1.21 Billion KRW | -107.84% |
| 2022 Q1 | 530.57 Million KRW | -84.27% |
| 2022 Q3 | 3.28 Billion KRW | -96.71% |
| 2022 Q4 | 1.52 Billion KRW | -53.64% |
| 2022 Q2 | 99.9 Billion KRW | 18729.4% |
| 2022 FY | 108.66 Billion KRW | 8046.51% |
| 2021 Q4 | 3.37 Billion KRW | 348.66% |
| 2021 FY | -1.36 Billion KRW | -142.47% |
| 2021 Q1 | -5.64 Billion KRW | -383.22% |
| 2021 Q2 | 153.53 Million KRW | 102.72% |
| 2021 Q3 | 751.73 Million KRW | 389.64% |
| 2020 Q1 | 552.16 Million KRW | -82.95% |
| 2020 Q3 | 647.2 Million KRW | 2248.74% |
| 2020 Q2 | 27.55 Million KRW | -95.01% |
| 2020 FY | 3.22 Billion KRW | -52.07% |
| 2020 Q4 | 1.99 Billion KRW | 207.99% |
| 2019 Q3 | -326.76 Million KRW | -109.51% |
| 2019 FY | 6.71 Billion KRW | 128.09% |
| 2019 Q1 | 370.85 Million KRW | -26.11% |
| 2019 Q4 | 3.23 Billion KRW | 1091.0% |
| 2019 Q2 | 3.43 Billion KRW | 826.55% |
| 2018 Q2 | 747.94 Million KRW | -58.61% |
| 2018 Q1 | 1.8 Billion KRW | 3247.96% |
| 2018 FY | 2.94 Billion KRW | 12.05% |
| 2018 Q3 | -111.28 Million KRW | -114.88% |
| 2018 Q4 | 501.91 Million KRW | 551.01% |
| 2017 Q1 | 1.93 Billion KRW | 89.59% |
| 2017 Q4 | -57.4 Million KRW | -113.09% |
| 2017 Q3 | 438.52 Million KRW | 41.99% |
| 2017 Q2 | 308.84 Million KRW | -84.07% |
| 2017 FY | 2.62 Billion KRW | -12.88% |
| 2016 Q1 | 1.1 Billion KRW | -98.83% |
| 2016 FY | 3.01 Billion KRW | -96.95% |
| 2016 Q4 | 1.02 Billion KRW | 4573.21% |
| 2016 Q3 | 21.88 Million KRW | -97.47% |
| 2016 Q2 | 865.26 Million KRW | -21.88% |
| 2015 FY | 98.85 Billion KRW | 2350.18% |
| 2015 Q4 | 94.73 Billion KRW | 30130.41% |
| 2015 Q3 | 313.36 Million KRW | -71.1% |
| 2015 Q2 | 1.08 Billion KRW | -60.22% |
| 2015 Q1 | 2.72 Billion KRW | 187.66% |
| 2014 FY | 4.03 Billion KRW | -49.28% |
| 2014 Q1 | 1.4 Billion KRW | 320.27% |
| 2014 Q4 | 947.65 Million KRW | -12.55% |
| 2014 Q3 | 1.08 Billion KRW | 80.96% |
| 2014 Q2 | 598.78 Million KRW | -57.37% |
| 2013 Q3 | 350.44 Million KRW | -80.4% |
| 2013 Q4 | -637.65 Million KRW | -281.95% |
| 2013 FY | 7.95 Billion KRW | -78.18% |
| 2013 Q1 | 6.45 Billion KRW | -38.7% |
| 2013 Q2 | 1.78 Billion KRW | -72.3% |
| 2012 Q4 | 10.52 Billion KRW | 265.74% |
| 2012 Q2 | 8.21 Billion KRW | -44.63% |
| 2012 FY | 36.45 Billion KRW | 3.9% |
| 2012 Q3 | 2.87 Billion KRW | -64.95% |
| 2012 Q1 | 14.83 Billion KRW | -38.78% |
| 2011 Q4 | 24.22 Billion KRW | 506.01% |
| 2011 Q1 | 5.87 Billion KRW | 1217.48% |
| 2011 Q2 | 983.77 Million KRW | -83.26% |
| 2011 FY | 35.08 Billion KRW | 457.1% |
| 2011 Q3 | 3.99 Billion KRW | 306.37% |
| 2010 FY | 6.29 Billion KRW | -21.77% |
| 2010 Q4 | 445.93 Million KRW | -40.18% |
| 2010 Q3 | 745.47 Million KRW | -35.45% |
| 2010 Q2 | 1.15 Billion KRW | -70.77% |
| 2010 Q1 | 3.95 Billion KRW | 36.91% |
| 2009 Q2 | 3.27 Billion KRW | 226.44% |
| 2009 Q3 | 886.13 Million KRW | -72.94% |
| 2009 Q1 | 1 Billion KRW | -58.5% |
| 2009 Q4 | 2.88 Billion KRW | 225.69% |
| 2009 FY | 8.04 Billion KRW | -76.44% |
| 2008 Q4 | 2.41 Billion KRW | -58.05% |
| 2008 Q3 | 5.76 Billion KRW | -70.44% |
| 2008 Q2 | 19.48 Billion KRW | 200.08% |
| 2008 Q1 | 6.49 Billion KRW | 86.72% |
| 2008 FY | 34.16 Billion KRW | 93.01% |
| 2007 FY | 17.69 Billion KRW | 0.0% |
| 2007 Q4 | 3.47 Billion KRW | -4.31% |
| 2007 Q3 | 3.63 Billion KRW | -25.4% |
| 2007 Q2 | 4.87 Billion KRW | -14.73% |
| 2007 Q1 | 5.71 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -191.619% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 136.112% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 64.856% |
| HANDOK Inc. | -28.79 Billion KRW | 27.282% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -148.846% |
| Yuhan Corporation | 93.5 Billion KRW | 122.394% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 288.276% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 15.602% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 114.32% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 696.843% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -735.492% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -909.73% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -362.799% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 193.768% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -191.619% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 684.391% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 82.294% |
| JW Holdings Corporation | 19.02 Billion KRW | 210.063% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 73.468% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 109.854% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 156.587% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 63.47% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 442.073% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 1358.815% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 518.421% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -191.619% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 156.65% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 118.781% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 156.587% |
| Yuhan Corporation | 93.5 Billion KRW | 122.394% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -28.869% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -440.334% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 442.215% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 156.587% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 210.764% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 143.39% |
| CKD Bio Corp. | -24.19 Billion KRW | 13.441% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 187.557% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 176.32% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 170.332% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 63.47% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 144.548% |
| Boryung Corporation | 40.2 Billion KRW | 152.088% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 33.16% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -735.492% |
| JW Lifescience Corporation | 28.14 Billion KRW | 174.406% |